^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTSL overexpression

    i
    Other names: CTSL, CTSL1, FLJ31037, Cathepsin L
    Entrez ID:
    1514
    1year
    Cathepsin L in Lung Adenocarcinoma: Prognostic Significance and Immunotherapy Response Through a Multi Omics Perspective. (PubMed, Cancer Inform)
    This study highlights the crucial role of CTSL as a prognostic biomarker in LUAD. This combined multicenter and omics-based analysis provides comprehensive insights into the biological role of CTSL, supporting its potential as a target for therapeutic intervention and a marker for prognosis in patients with LUAD.
    Journal • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CTSL (Cathepsin L)
    |
    CTSL overexpression
    over1year
    Cathepsin L promotes oesophageal squamous cell carcinoma development and may be associated with tumour-associated macrophages. (PubMed, Heliyon)
    CTSL emerged as a crucial gene in ESCC that influences patient prognosis and immunity, particularly in association with M2 macrophages. Therefore, targeting or modulating CTSL levels may provide new therapeutic strategies for patients with ESCC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CTSL (Cathepsin L)
    |
    CTSL overexpression
    over2years
    CTSL, a prognostic marker of breast cancer, that promotes proliferation, migration, and invasion in cells in triple-negative breast cancer. (PubMed, Front Oncol)
    CTSL might involve into the regulation of the proliferation, invasion, and metastasis of TNBC. Thus, CTSL would be a novel, potential therapeutic, and prognostic target of TNBC.
    Journal
    |
    CTSL (Cathepsin L)
    |
    CTSL overexpression